Paradox Immunotherapeutics Incorporated
$73,524.00 CAD
≈ 11 months of average Canadian pay
- Department
- National Research Council Canada
- Recipient country
- Canada
- Fiscal year
- 2024-2025
- Agreement period
- December 4, 2024 – July 31, 2025
- Reference
- nrc-cnrc:172-2024-2025-Q4-1027009
Published purpose
As part of Multinational Corporate Collaboration Program, the project “PACAAL” will focus on using established mouse models to evaluate 4 top candidate antibodies co-developed by Paradox and Eli Lilly for the treatment of kappa light chain amyloidosis. After in vivo evaluation of the candidates, we will nominate a development candidate to move forward in IND-enabling studies.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.
Good value
Local impact
Needs context
Questionable
Success story
Wasteful
View official source record
Imported July 30, 2026 from open.canada.ca Grants & Contributions